KYOTO, Japan, May 17th, 2024 – OMRON Healthcare Co., Ltd. (Head Office: Muko, Kyoto, President & CEO: Ayumu Okada) announced its presence at Heart Rhythm 2024, the Annual Meeting of the Heart Rhythm Society (HRS) in the U.S. At Heart Rhythm 2024, the Company will showcase its upper-arm blood pressure monitor with ECG technology, Complete, and a series of home-use blood pressure monitors.

In addition, OMRON will support a CME accredited breakfast symposium¹ discussing early detection of atrial fibrillation (AFib) and the management of hypertensive patients. The result of a clinical trial utilizing new technology to detect the AFib using OMRON blood pressure monitors will be also presented at the symposium.

 

Heart Rhythm 2024 is organized by the Heart Rhythm Society (HRS) and provides a platform to advance the field of electrophysiology (EP) and improve patient outcomes through the exchange of groundbreaking science, cutting-edge technologies, and life-saving therapies. At the CME Breakfast Symposium at Heart Rhythm 2024, Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at the Mount Sinai Hospital and the Mount Sinai Health System, will moderate it under the theme of and discuss AFib detection among hypertensive patients and the clinical significance of the early detection of AFib by using cutting-edge technology with other prominent experts.

 

“Going for Zero” is the vision of OMRON’s cardiovascular domain: Reducing the incidence of cerebrovascular and cardiovascular diseases to zero and one of its goals is to provide a solution for the early detection of AFib. Early AFib detection can help prevent serious complications such as heart attack or stroke, however, the challenge is that about 40% of patients are asymptomatic, making early detection difficult. Study shows that hypertensive patients develop AFib three times higher than individuals with a normal range of blood pressure². Since 2019, the Company has been expanding devices and services globally including upper arm blood pressure monitors with built-in ECG technology and home-use portable ECG that quickly detects the possibility of AFib. The Company actively participates in academic conference activities and clinical studies held in various countries around the world and has been working on advancing the early detection technology of AFib in collaboration with healthcare professionals and researchers. The Company will continue to promote academic activities globally, develop devices and services, and contribute to empowering people worldwide to live life to the fullest.